Turan Yücel, NazliKandemir, ÜmmühanÜçel, Umut IrfanCan, Özgür DevrimDemir Özkay, Ümide2024-10-042024-10-0420222564-6524https://doi.org/10.33483/jfpau.1149796https://search.trdizin.gov.tr/tr/yayin/detay/1155464http://hdl.handle.net/20.500.12403/3920Objective: The incidence of emotional and cognitive disorders are higher in diabetic patients with respect to the general population. In this study, it was aimed to investigate the efficacy of reboxetine, a clinically prescribed drug for its antidepressant effect, on behavioral and cognitive alterations caused by diabetes in rats. Material and Method: An experimental diabetes model in rats was induced with a single 50 mg/kg injection of streptozotocin (i.v.). Reboxetine treatment was started 4 weeks after induction of diabetes in order to observe diabetic complications. Depression and anxiety levels of experimental animals were investigated by modified forced swimming and elevated plus-maze tests, respectively; cognitive performances were evaluated by Morris water-maze and passive avoidance experiments. The motor activities of the animals were also examined with the activity cage and Rota-rod tests. Result and Discussion: Obtained results indicated that the depression and anxiety levels of diabetic rats were increased and their cognitive performances were weakened. Reboxetine treatment (8 and 16 mg/kg) for two weeks reduced the elevated depression and anxiety levels in diabetic rats, while significantly improving their weakened cognitive performance. The findings indicated that reboxetine might possess a therapeutic potential for the cure of behavioral and cognitive impairements concomitant with diabetes. © 2022 University of Ankara. All rights reserved.trinfo:eu-repo/semantics/openAccessAnxietycognitiondepressionDiabetes mellitusreboxetineArticle47110.33483/jfpau.11497962-s2.0-85145463430N/A1155464